Sections
| Title | Starting Page | Number of Pages |
|---|
| Table of Contents | 2 | 3 |
| List of Tables | 4 | 1 |
| List of Figures | 4 | 1 |
| Introduction | 5 | 1 |
| Global Markets Direct Report Coverage | 5 | 1 |
| Maternal Embryonic Leucine Zipper Kinase (Protein Kinase Eg3 or Tyrosine Protein Kinase MELK or Protein Kinase PK38 or MELK or EC 2.7.11.1) Overview | 6 | 1 |
| Therapeutics Development | 7 | 3 |
| Maternal Embryonic Leucine Zipper Kinase (Protein Kinase Eg3 or Tyrosine Protein Kinase MELK or Protein Kinase PK38 or MELK or EC 2.7.11.1) Products under Development by Stage of Development | 7 | 1 |
| Maternal Embryonic Leucine Zipper Kinase (Protein Kinase Eg3 or Tyrosine Protein Kinase MELK or Protein Kinase PK38 or MELK or EC 2.7.11.1) Products under Development by Therapy Area | 8 | 1 |
| Maternal Embryonic Leucine Zipper Kinase (Protein Kinase Eg3 or Tyrosine Protein Kinase MELK or Protein Kinase PK38 or MELK or EC 2.7.11.1) Products under Development by Indication | 9 | 1 |
| Maternal Embryonic Leucine Zipper Kinase (Protein Kinase Eg3 or Tyrosine Protein Kinase MELK or Protein Kinase PK38 or MELK or EC 2.7.11.1) Pipeline Products Glance | 10 | 2 |
| Late Stage Products | 10 | 1 |
| Early Stage Products | 11 | 1 |
| Maternal Embryonic Leucine Zipper Kinase (Protein Kinase Eg3 or Tyrosine Protein Kinase MELK or Protein Kinase PK38 or MELK or EC 2.7.11.1) Products under Development by Companies | 12 | 2 |
| Maternal Embryonic Leucine Zipper Kinase (Protein Kinase Eg3 or Tyrosine Protein Kinase MELK or Protein Kinase PK38 or MELK or EC 2.7.11.1) Products under Development by Universities/Institutes | 14 | 2 |
| Maternal Embryonic Leucine Zipper Kinase (Protein Kinase Eg3 or Tyrosine Protein Kinase MELK or Protein Kinase PK38 or MELK or EC 2.7.11.1) Therapeutics Assessment | 16 | 6 |
| Assessment by Monotherapy/Combination Products | 16 | 1 |
| Assessment by Mechanism of Action | 17 | 1 |
| Assessment by Route of Administration | 18 | 2 |
| Assessment by Molecule Type | 20 | 2 |
| Maternal Embryonic Leucine Zipper Kinase (Protein Kinase Eg3 or Tyrosine Protein Kinase MELK or Protein Kinase PK38 or MELK or EC 2.7.11.1) Companies Involved in Therapeutics Development | 22 | 6 |
| Arrien Pharmaceuticals, LLC | 22 | 1 |
| Bionomics Limited | 23 | 1 |
| Novartis AG | 24 | 1 |
| OncoTherapy Science, Inc. | 25 | 1 |
| Selvita S.A. | 26 | 1 |
| SignalChem Lifesciences Corp | 27 | 1 |
| Maternal Embryonic Leucine Zipper Kinase (Protein Kinase Eg3 or Tyrosine Protein Kinase MELK or Protein Kinase PK38 or MELK or EC 2.7.11.1) Drug Profiles | 28 | 8 |
| ARN-7016 Drug Profile | 28 | 1 |
| Drugs to Inhibit MELK for Solid Tumors Drug Profile | 29 | 1 |
| OTS-167 Drug Profile | 30 | 2 |
| SEL-128 Drug Profile | 32 | 1 |
| Small Molecules to Inhibit MELK for Oncology Drug Profile | 33 | 1 |
| Small Molecules to Inhibit MELK for Oncology Drug Profile | 34 | 1 |
| Vaccine to Target FOXM1, MELK, HJURP, VEGFR-1 and VEGFR-2 for Ovarian Cancer Drug Profile | 35 | 1 |
| Maternal Embryonic Leucine Zipper Kinase (Protein Kinase Eg3 or Tyrosine Protein Kinase MELK or Protein Kinase PK38 or MELK or EC 2.7.11.1) Dormant Projects | 36 | 1 |
| Maternal Embryonic Leucine Zipper Kinase (Protein Kinase Eg3 or Tyrosine Protein Kinase MELK or Protein Kinase PK38 or MELK or EC 2.7.11.1) Featured News &Press Releases | 37 | 4 |
| Mar 17, 2016: The Phase I clinical study of OTS167, MELK specific inhibitor, in Australia Completed | 37 | 1 |
| Feb 29, 2016: Publication of a paper describing the possible effect of a MELK inhibitor OTS167 on kidney cancer | 37 | 1 |
| Feb 26, 2016: Publication for possible biomarkers of OTS167, MELK inhibitor | 38 | 1 |
| Feb 12, 2016: Publication of a paper describing the possible effect of a MELK inhibitor, OTS167, on small cell lung cancer | 38 | 1 |
| Jan 25, 2016: The commencement of Phase I/II clinical study of OTS167, MELK specific inhibitor, for Acute Myeloid Leukemia patients in USA | 38 | 1 |
| Jan 05, 2016: MELK inhibitor, OTS167, Phase I clinical study commencement in Australia | 39 | 1 |
| Jun 18, 2015: The commencement of patient enrollment in Phase I clinical study of OTS167, a novel small molecule compound targeting cancer stem cells | 39 | 1 |
| Apr 15, 2013: Selvita Reports Data from SEL128 Oncology Program At AACR Annual Meeting 2013 | 40 | 1 |
| Appendix | 41 | 2 |
| Methodology | 41 | 1 |
| Coverage | 41 | 1 |
| Secondary Research | 41 | 1 |
| Primary Research | 41 | 1 |
| Expert Panel Validation | 41 | 1 |
| Contact Us | 41 | 1 |
| Disclaimer | 42 | 1 |